III.J.05. Dengue Virus Vaccines. By FY97, select the best methodology for vaccine development. By FY99, transition to advanced development a candidate polyvalent dengue virus vaccine to protect 80 percent of immunized troops from dengue fever caused by dengue virus types 1, 2, 3, and 4.
Supports: Army Modernization Plan, Medical Annex OProject, Sustain, and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.
|STO Manager:||TSO:||TRADOC POC:|
|COL W. H. Bancroft||MAJ Mark Seymour||Herbert Russakoff|
|MRMC||SARD-TM||CSS Battle Lab|